These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

636 related items for PubMed ID: 25609557

  • 1. Cost-effectiveness of adding rituximab to splenectomy and romiplostim for treating steroid-resistant idiopathic thrombocytopenic purpura in adults.
    Kikuchi K, Miyakawa Y, Ikeda S, Sato Y, Takebayashi T.
    BMC Health Serv Res; 2015 Jan 22; 15():2. PubMed ID: 25609557
    [Abstract] [Full Text] [Related]

  • 2. [Cost-per-responder analysis comparing romiplostim to rituximab in the treatment of adult primary immune thrombocytopenia in Spain].
    López MF, Mingot ME, Valcárcel D, Vicente García V, Perrin A, Campos Tapias I.
    Med Clin (Barc); 2015 May 08; 144(9):389-96. PubMed ID: 24565604
    [Abstract] [Full Text] [Related]

  • 3. The burden of immune thrombocytopenia in adults: evaluation of the thrombopoietin receptor agonist romiplostim.
    Deuson R, Danese M, Mathias SD, Schoonen M, Fryzek J.
    J Med Econ; 2012 May 08; 15(5):956-76. PubMed ID: 22533524
    [Abstract] [Full Text] [Related]

  • 4. Romiplostim for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a single technology appraisal.
    Mowatt G, Boachie C, Crowther M, Fraser C, Hernández R, Jia X, Ternent L.
    Health Technol Assess; 2009 Sep 08; 13 Suppl 2():63-8. PubMed ID: 19804691
    [Abstract] [Full Text] [Related]

  • 5. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
    Zaja F, Barcellini W, Cantoni S, Carpenedo M, Caparrotti G, Carrai V, Di Renzo N, Santoro C, Di Nicola M, Veneri D, Simonetti F, Liberati AM, Ferla V, Paoloni F, Crea E, Volpetti S, Tuniz E, Fanin R.
    Am J Hematol; 2016 May 08; 91(5):E293-5. PubMed ID: 26910388
    [Abstract] [Full Text] [Related]

  • 6. Romiplostim in chronic immune thrombocytopenic purpura.
    Cersosimo RJ.
    Clin Ther; 2009 Sep 08; 31(9):1887-907. PubMed ID: 19843480
    [Abstract] [Full Text] [Related]

  • 7. Romiplostim in adults with newly diagnosed or persistent immune thrombocytopenia.
    Lozano ML, Godeau B, Grainger J, Matzdorff A, Rodeghiero F, Hippenmeyer J, Kuter DJ.
    Expert Rev Hematol; 2020 Dec 08; 13(12):1319-1332. PubMed ID: 33249935
    [Abstract] [Full Text] [Related]

  • 8. Effect of a thrombopoietin receptor agonist on use of intravenous immune globulin in patients with immune thrombocytopenia.
    Zeller MP, Heddle NM, Kelton JG, Hamilton K, Wang G, Sholapur N, Carruthers J, Hsia C, Blais N, Toltl L, Hamm C, Pearson MA, Arnold DM.
    Transfusion; 2016 Jan 08; 56(1):73-9. PubMed ID: 26400824
    [Abstract] [Full Text] [Related]

  • 9. Plateletpheresis for postsplenectomy rebound thrombocytosis in a patient with chronic immune thrombocytopenic purpura on romiplostim.
    Raval JS, Redner RL, Kiss JE.
    J Clin Apher; 2013 Aug 08; 28(4):321-4. PubMed ID: 23450778
    [Abstract] [Full Text] [Related]

  • 10. Successful treatment of Immune Thrombocytopenic Purpura (ITP) with the thrombopoietin-mimetic romiplostim.
    Meletis J, Katsandris A, Raptis SD, Mantzourani M.
    Med Sci Monit; 2010 Aug 08; 16(8):CS100-2. PubMed ID: 20671616
    [Abstract] [Full Text] [Related]

  • 11. Cost effectiveness of romiplostim for the treatment of chronic immune thrombocytopenia in Ireland.
    Lee D, Thornton P, Hirst A, Kutikova L, Deuson R, Brereton N.
    Appl Health Econ Health Policy; 2013 Oct 08; 11(5):457-69. PubMed ID: 23857462
    [Abstract] [Full Text] [Related]

  • 12. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP).
    Mazza P, Minoia C, Melpignano A, Polimeno G, Cascavilla N, Di Renzo N, Specchia G.
    Ann Hematol; 2016 Jan 08; 95(2):239-44. PubMed ID: 26596973
    [Abstract] [Full Text] [Related]

  • 13. A large observational study of patients with primary immune thrombocytopenia receiving romiplostim in European clinical practice.
    Steurer M, Quittet P, Papadaki HA, Selleslag D, Viallard JF, Kaiafa G, Janssens A, Kozak T, Wadenvik H, Schoonen M, Belton L, Kreuzbauer G.
    Eur J Haematol; 2017 Feb 08; 98(2):112-120. PubMed ID: 27557853
    [Abstract] [Full Text] [Related]

  • 14. Use of the novel thrombopoietin receptor-agonist romiplostim, in combination with steroids and immunoglobulins for the increase of platelets prior to splenectomy, in refractory immune thrombocytopenia: a case report.
    Sivera P, Ruella M, Gueli A, Hu H, Wade M, Tarella C.
    Blood Coagul Fibrinolysis; 2012 Jun 08; 23(4):331-4. PubMed ID: 22343685
    [Abstract] [Full Text] [Related]

  • 15. The Cost-effectiveness of Eltrombopag for the Treatment of Immune Thrombocytopenia in the United States.
    Tremblay G, Dolph M, Roy AN, Said Q, Forsythe A.
    Clin Ther; 2020 May 08; 42(5):860-872.e8. PubMed ID: 32199608
    [Abstract] [Full Text] [Related]

  • 16. Treatment patterns and outcomes of second-line rituximab and thrombopoietin receptor agonists in adult immune thrombocytopenia: A Canadian retrospective cohort study.
    Podstawka J, Wall E, Bolster L, Patterson JM, Goodyear MD, Rydz N, Sun HL.
    Thromb Res; 2022 Dec 08; 220():5-11. PubMed ID: 36257098
    [Abstract] [Full Text] [Related]

  • 17. Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program.
    Khellaf M, Michel M, Quittet P, Viallard JF, Alexis M, Roudot-Thoraval F, Cheze S, Durand JM, Lefrère F, Galicier L, Lambotte O, Panelatti G, Slama B, Damaj G, Sebahoun G, Gyan E, Delbrel X, Dhedin N, Royer B, Schleinitz N, Rossi JF, Mahévas M, Languille L, Bierling P, Godeau B.
    Blood; 2011 Oct 20; 118(16):4338-45. PubMed ID: 21832276
    [Abstract] [Full Text] [Related]

  • 18. Primary immune thrombocytopenia (ITP) treated with romiplostim in routine clinical practice: retrospective study from the United Kingdom ITP Registry.
    Doobaree IU, Newland A, McDonald V, Nandigam R, Mensah L, Leroy S, Seesaghur A, Patel H, Wetten S, Provan D.
    Eur J Haematol; 2019 May 20; 102(5):416-423. PubMed ID: 30758874
    [Abstract] [Full Text] [Related]

  • 19. Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura.
    Jamali F, Lemery S, Ayalew K, Robottom S, Robie-Suh K, Rieves D, Pazdur R.
    Oncology (Williston Park); 2009 Jul 20; 23(8):704-9. PubMed ID: 19711585
    [Abstract] [Full Text] [Related]

  • 20. [Reference guide for the treatment of adult idiopathic thrombocytopenic purpura].
    Kashiwagi H.
    Rinsho Ketsueki; 2020 Jul 20; 61(9):1325-1330. PubMed ID: 33162532
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.